Molecular advances in gynecologic oncology

Current Opinion in Oncology

Volumn 11, Issue 5, 1999, Pages 394-400

  Cass, Ilana ^a   Baldwin, Rae Lynn ^a   Karlan, Beth Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN KINASE; PROTEIN P53;

BASE MISPAIRING; CANCER GENETICS; CANCER PREVENTION; CARCINOGENESIS; DNA REPAIR; ENDOMETRIUM CANCER; FEMALE; GENE THERAPY; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCREENING TEST; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

FEMALE; GENES, TUMOR SUPPRESSOR; GENITAL NEOPLASMS, FEMALE; GTP-BINDING PROTEINS; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; ONCOGENES; PROTEIN KINASES;

EID: 0032843636     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199909000-00013     Document Type: Review

References (42)

1. Vogelstein B, Fearon E, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al.: Genetic alterations during colorectal tumor development. N Engl J Med 1988, 319:525-532.
2. Parker MF, Sausville EA, Birrer MJ: Basic biology and biochemistry of gynecologic cancer. In Principles and Practice of Gynecologic Oncology, edn 2. Edited by Hoskins W, Perez C, Young R. Philadelphia: Lippincott-Raven. 1997:61-86.
3. Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY: Altered expression of transforming growth factor beta (TGF-β) ligands and receptors in primary and recurrent ovarian carcinomas. Cancer 1999, 85:658-668.
4. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC: The biology of ovarian cancer. Semin Oncol 1998, 25:281-304. A comprehensive summary of current biologic understanding of ovarian carcino-genesis and drug resistance.
5. Cirisano FD, Karlan BY: The role of HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Invest 1996, 3:99-105.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
7. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al.: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998, 16:2659-2671. An important phase II trial that demonstrates that gene therapy with HER 2/neu is well tolerated and has promising results in patients with breast cancer.
8. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, et al.: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 1998, 58:2500-2503.
9. Liu A, Testa JR, Hamilton TC, Jove R, Nicosia SV, Cheng JO: AKT2, a member of the protein kinase B family, is activated by growth factors, v-Haras and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 1998, 58:2973-2977.
10. Lynch HT, Casey MJ, Lynch J, White EK, Godwin AK: Genetics and ovarian carcinoma. Semin Oncol 1998, 25:265-280.
11. Shayesteh L, Lu Y, Kuo W, Baldocci R, Godfrey T, Collins C, et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999, 21:99-102. This article provides a model for establishing that a candidate gene is an oncogene through experiments that demonstrate increased expression and the functional significance of, gene product in cancer cells.
12. Tlsty TD: A molecular blueprint for targeting cancer? Nat Genet 1999, 21:64-65.
13. Godwin A, Schulz D, Hamilton T, Knudson AG: Oncogenes and tumor suppressor genes. In Principles and Practice of Gynecologic Oncology, edn 2. Edited by Hoskins W, Perez C, Young R. Philadelphia: Lippincott-Raven. 1997:107-148.
14. Al-Jehani RM, Jeyarajah AR, Hagen BJ, Hogdall EV, Oram DH, Jacobs IJ: Model for molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis. J Natl Cancer Inst 1998, 90:40-542.
15. Knudson AG: Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996, 122:135-140.
16. Hamilton TC, Johnson SW, Godwin AK: Molecular biology of gynecologic malignancies. Cancer Treat Res 1998, 95:103-114.
17. Kersemaekers AM, Kenter GG, Hermans J, Fleuren GJ, van de Vijer MJ: Allelic loss and prognosis in carcinoma of the uterine cervix. Int J Cancer 1998, 79:411-117.
18. Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmedian M, et al.: Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papilloma virus type. J Natl Cancer Inst 1998, 90:433-439. A good model for how to critically evaluate whether the FHIT gene may be a tumor-suppressor gene in cervical cancer.
19. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barret JC, Berchuck A: PTEN mutations mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998, 4:3005-3010.
20. Risinger JI, Umar A, Boyd J, Berchuck A, Knukel TA, Barrett JC: Mutations of MSH3 in endometrial cancer and evidence for its role in heteroduplex repair. Nat Genet 1996, 14:102-105.
21. Swisher EM, Mutch DG, Herzog TJ, Rader JS, Kowalski LD, Elbendary A, Goodfellow PJ: Analysis of MSH3 in endometrial cancers with defective DNA mismatch repair. J Soc Gynecol Invest 1998, 5:210-216.
22. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett C, et al.: The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998, 58:3579-3585.
23. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-196. A comprehensive review of DNA methylation and its potential role in carcinogenesis.
24. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998, 95:6870-6875. This article provides strong evidence that hypermethylation can inactivate tumor-suppressor genes through a series of experiments that demonstrate that hypermethylation of hMLH1 occurs frequently, and that the reversal of methylation restores hMLH1 expression and function in colon cancer cell lines.
25. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167. A review of how epigenetic mechanisms of gene inactivation, including DNA methylation, can contribute to cancer.
26. Lin H, Huber R, Schlessinger D, Morin PJ: Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999, 59:807-810.
27. McCluskey LL, Chen C, Delgadillo E, Felix JC, Muderspach LI, Dubeau L: Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 1999, 72:87-92.
28. Lane DP: p53, guardian of the genome. Nature 1992, 358:15-16.
29. Mujoo K, Catino JJ, Maneval DC, Gutterman JU: Studies on the molecular mechanism of growth inhibition with p53 adenoviral construct in human ovarian cancer. Int J Gynecol Cancer 1998, 8:233-241.
30. Akashi M, Koeffler HP: Li-Fraumeni syndrome and the role of p53 tumor suppressor gene in cancer susceptibility. Clin Obstet Gynecol 1998, 41:172-199.
31. DiCioccio RA, Werness BA, Peng R, Allen HJ, Piver MS: Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet 1998, 105:93-102. A good summary of the methods of detection and heterogeneity of p53 mutations in ovarian cancers.
32. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, et al.: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996, 13:1971-1981.
33. Havirlesky L, Berchuck A, Hamdan H, Walsh K, Leon J: Relationship between p53 mutation, p53 overexpression and survival in advanced stage ovarian cancers treated on Gynecologic Oncology Group protocols 114 and 132. Gynecol Oncol 1999, 72:445.
34. Mujoo K, Maneval DC, Anderson SC, Gutterman JU: Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996, 12:1617-1623.
35. Buller R, Pegram M, Runnebaum I, Horowitz JA, Buekers R, Salko TP, et al.: A phase I/II trial of recombinant adenoviral human p53 (SCH58500) intraperitoneal (ip) gene therapy in recurrent ovarian cancer. Gynecol Oncol 1999, 72:453.
36. Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiere A, Clough K, et al.: Human papillomavirus genotype as a major determinant of the course cervical cancer. J Clin Oncol 1998, 16(8):2613-2619.
37. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al.: Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393:229-234.
38. Lanham S, Campbell I, Watt P, Gornall R: p53 polymorphism and risk of cervical cancer. Lancet 1998, 352:1631.
39. Berchuck A, Carney M, Lancaster JM, Marks J, Futreal AP: Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2. Clin Obstet and Gynecol 1998, 41:157-166.
40. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Genetic heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62:676-689.
41. Blackwood MA, Weber BL: BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998, 16:1969-1977. A comprehensive description of the incidence of mutations in BRCA1 and BRCA2 and their function in both normal and cancer cells.
42. Husain A, He G, Venkatraman ES, Spriggs DR: BRCA1 up-regulation is associated with repair mediated resistance to cis-diamminechloroplatinum (ii). Cancer Res 1998, 58:1120-1123. The investigators begin with the interesting observation that BRCA1 is up-regulated in cisplatin-resistant cell lines and then demonstrate its role in DNA damage repair, thereby elucidating a possible function of BRCA1 in ovarian cancer.